(untitled)Christina Yau, Adam L. Asare, Marie Osdoit et al.|Edinburgh Research Explorer|0Cited by 353
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancerP. Tarantino, G. Curigliano, Jorge S. Reis‐Filho et al.|Annals of Oncology|2023Cited by 298
Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug responseDimitra Georgopoulou, Shelley Harris, Maurizio Callari et al.|Nature Communications|2021Cited by 59
Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast CancerAbigail Shea, Alejandra Bruna, Yaniv Lubling et al.|Cancer Research|2024Cited by 7
Data from Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast CancerAbigail Shea, Alejandra Bruna, Yaniv Lubling et al.|Unknown|2025Cited by 1